BCKDK and type 2 diabetes mellitus: Here, we performed focussed cis-MR analysis with genetic variants from PPM1K, DBT and BCAT2 gene regions as instruments to directly assess the potential therapeutic effect of inhibiting BCKDK kinase on reducing T2D risk.